Citigroup Inc Eliem Therapeutics, Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 22,731 shares of ELYM stock, worth $93,424. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,731
Previous 21,417
6.14%
Holding current value
$93,424
Previous $109,000
14.68%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ELYM
# of Institutions
76Shares Held
51MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$6.19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...